A bacterial ‘lipoprotein’ machine can be repurposed to build lipidated macrocyclic peptides
A 2026 PNAS paper reports a way to co-opt bacterial lipoprotein processing to biosynthesize lipidated macrocyclic peptides. It is a methods advance that could matter for lipopeptide discovery and tuning pharmacology.
A lot of peptide drug development is really chemistry + logistics: how do you make enough material, and how do you tune the parts of the molecule that control stability, distribution, and exposure.
A new PNAS paper describes a clever option for one of the most important tuning knobs: lipidation.
Study: Proceedings of the National Academy of Sciences (2026). https://pubmed.ncbi.nlm.nih.gov/41911463/ (DOI: https://doi.org/10.1073/pnas.2532672123)
What they’re claiming (in plain language)
Bacteria already have a native pathway for making lipoproteins, including enzymatic steps that attach lipid groups. The authors report they can co-opt that machinery to biosynthesize lipidated macrocyclic peptides.
If true and generalizable, that is interesting because lipidation is one of the most proven ways to:
- increase apparent half-life
- change tissue distribution
- improve potency by increasing local membrane association
(You see versions of this logic in marketed peptide drugs, although the exact chemistry varies.)
What changed / what is new
The novelty here is the combination:
- macrocyclic peptides
- lipidation
- biosynthetic production using an existing bacterial processing route
That is different from “lipidate it by hand in a chemistry lab,” and different from standard recombinant expression.
Why it might matter
If this approach is robust, it could make it easier to explore lipidated macrocycles at scale:
- faster iteration (a wider design space becomes practical)
- potentially lower friction for screening and optimization
- a more direct path to systematically testing how different lipid handles alter properties
This is not automatically a “drug platform,” but it could be a useful tool for groups working on antimicrobial peptides, membrane-active macrocycles, or other lipopeptide-like modalities.
What we know vs what we don’t know
What we know:
- The paper reports a biosynthetic strategy to generate lipidated macrocyclic peptides by leveraging a bacterial lipoprotein pathway.
What we don’t know:
- How broad the substrate scope is (which macrocycles, which lipid groups).
- How predictable the lipidation is (heterogeneity is a common headache).
- Whether the resulting compounds have clean, drug-like profiles (PK, safety, off-target membrane effects).
Further reading
- Co-opting the bacterial lipoprotein pathway for the biosynthesis of lipidated macrocyclic peptides. PNAS (2026). https://pubmed.ncbi.nlm.nih.gov/41911463/ (DOI: https://doi.org/10.1073/pnas.2532672123)